These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36282874)

  • 1. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
    Meric-Bernstam F; Sweis RF; Kasper S; Hamid O; Bhatia S; Dummer R; Stradella A; Long GV; Spreafico A; Shimizu T; Steeghs N; Luke JJ; McWhirter SM; Müller T; Nair N; Lewis N; Chen X; Bean A; Kattenhorn L; Pelletier M; Sandhu S
    Clin Cancer Res; 2023 Jan; 29(1):110-121. PubMed ID: 36282874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
    Meric-Bernstam F; Sweis RF; Hodi FS; Messersmith WA; Andtbacka RHI; Ingham M; Lewis N; Chen X; Pelletier M; Chen X; Wu J; McWhirter SM; Müller T; Nair N; Luke JJ
    Clin Cancer Res; 2022 Feb; 28(4):677-688. PubMed ID: 34716197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
    Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
    Schöffski P; Tan DSW; Martín M; Ochoa-de-Olza M; Sarantopoulos J; Carvajal RD; Kyi C; Esaki T; Prawira A; Akerley W; De Braud F; Hui R; Zhang T; Soo RA; Maur M; Weickhardt A; Krauss J; Deschler-Baier B; Lau A; Samant TS; Longmire T; Chowdhury NR; Sabatos-Peyton CA; Patel N; Ramesh R; Hu T; Carion A; Gusenleitner D; Yerramilli-Rao P; Askoxylakis V; Kwak EL; Hong DS
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
    Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
    Curigliano G; Gelderblom H; Mach N; Doi T; Tai D; Forde PM; Sarantopoulos J; Bedard PL; Lin CC; Hodi FS; Wilgenhof S; Santoro A; Sabatos-Peyton CA; Longmire TA; Xyrafas A; Sun H; Gutzwiller S; Manenti L; Naing A
    Clin Cancer Res; 2021 Jul; 27(13):3620-3629. PubMed ID: 33883177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
    Meric-Bernstam F; Sweis RF; Hodi FS; Messersmith WA; Andtbacka RHI; Ingham M; Lewis N; Chen X; Pelletier M; Chen X; Wu J; Dubensky TW; McWhirter SM; Müller T; Nair N; Luke JJ
    Clin Cancer Res; 2023 Jun; 29(12):2336. PubMed ID: 37309603
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies.
    Ahmed J; Stephen B; Yang Y; Kwiatkowski E; Ejezie CL; Pant S
    J Immunother Precis Oncol; 2024 May; 7(2):73-81. PubMed ID: 38721402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
    Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.
    Minami H; Doi T; Toyoda M; Imamura Y; Kiyota N; Mitsuma A; Shimokata T; Naito Y; Matsubara N; Tajima T; Tokushige K; Ishihara K; Cameron S; Ando Y
    Cancer Sci; 2021 Feb; 112(2):725-733. PubMed ID: 33031626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase Ib/II trial of capmatinib plus spartalizumab
    Santoro A; Assenat E; Yau T; Delord JP; Maur M; Knox J; Cattan S; Lee KH; Del Conte G; Springfeld C; Leo E; Xyrafas A; Fairchild L; Mardjuadi F; Chan SL
    JHEP Rep; 2024 Apr; 6(4):101021. PubMed ID: 38617599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
    Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
    Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
    Lin CC; Garralda E; Schöffski P; Hong DS; Siu LL; Martin M; Maur M; Hui R; Soo RA; Chiu J; Zhang T; Ma B; Kyi C; Tan DS; Cassier PA; Sarantopoulos J; Weickhardt A; Carvajal RD; Spratlin J; Esaki T; Rolland F; Akerley W; Deschler-Baier B; Rispoli L; Samant TS; Chowdhury NR; Gusenleitner D; Kwak EL; Askoxylakis V; De Braud F
    Oncoimmunology; 2024; 13(1):2290787. PubMed ID: 38170160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
    Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CX-072 (pacmilimab), a Probody
    Naing A; Thistlethwaite F; De Vries EGE; Eskens FALM; Uboha N; Ott PA; LoRusso P; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Randhawa M; Durm G; Gil-Martin M; Stroh M; Hannah AL; Arkenau HT; Spira A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation.
    Ji N; Wang M; Tan C
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.